Skip to content

Abstract 16691: High-Dose versus Standard-Dose Influenza Vaccine in Older Adults with Neurological and Cerebrovascular Disease: A Prespecified Analysis of the DANFLU-2 Trial

Nov 2026 · Circulation · 0 citations

Abstract

Background: Adults with neurological or cerebrovascular (NeCVD) disease have an elevated risk of influenza-related complications. Whether HD-IIV provides greater relative benefit over SD-IIV in this population is uncertain. Objective: To evaluate the relative vaccine effectiveness (rVE) of high-dose inactivated influenza vaccine (HD-IIV) compared with standard-dose inactivated influenza vaccine (SD-IIV) among older adults with and without NeCVD disease. Methods: We conducted a prespecified secondary analysis of DANFLU-2, a pragmatic, registry-based, open-label, active-controlled, individually randomized trial in Denmark across the 2022/23, 2023/24, and 2024/25 influenza seasons. Adults aged ≥65 years were randomized 1:1 to HD-IIV or SD-IIV. Outcome data were obtained from nationwide health registries. The primary outcome was hospitalization for influenza or pneumonia. rVE was calculated as rVE = (1 – RR) х 100%. The number needed to vaccinate (NNV) was calculated as 1/(SD-IIV event rate х rVE). NNV was calculated only for endpoints with lower limit of confidence interval of overall crude rVE estimates > 0. NNV within subgroups was calculated using the overall rVE estimate for the outcome in case no significant effect modification was observed. Results: Among 332,438 participants, 166,218 were randomized to HD-IIV and 166,220 to SD-IIV. NeCVD was present in 24,467 (7.4%) of participants. Event rates were higher among participants with NeCVD than those without, including hospitalization for influenza or pneumonia (25.0 vs 10.6 per 1,000 participant-years), cardiorespiratory hospitalization (73.9 vs 35.7), and stroke hospitalization (13.1 vs 4.0). rVE was consistent among participants with and without NeCVD for most outcomes (Pinteraction>0.05). As a result, NNVs were lower among participants with neurological or cerebrovascular disease. For example, for the primary outcome of hospitalization for influenza and pneumonia, rVE was 12.4% (95% CI, -8.1 to 29.0; NNV=502) among those with NeCVD vs 4.9% (95% CI, -3.9 to 13.1; NNV=3,070) among those without. The rVEs for NeCVD outcomes were generally neutral, including all-cause neurological hospitalizations [rVE -14.6% (95% CI, -47.2 to 10.6)] and cerebrovascular hospitalizations [rVE 6.9% (95% CI, -4.4 to 17.0)]. The risk of hemorrhagic stroke was lower with HD-IIVvs SD-IIV [rVE 28.4% (95% CI, 2.4 to 47.7)]. No significant differences were observed for dementia outcomes [rVE 21.7% (95% CI, -51.6 to 60.2)] (Figure 1). Conclusions: The rVE of HD-IIV vs. SD-IIV was consistent across participants with and without knowing NeCVD. Estimated NNVs for HD-IIV vs. SD-IIV were lower among those with NeCVD due to higher underlying event rates. These findings support HD-IIV for high-risk neurovascular populations, where similar rVE may yield greater absolute benefit.

View source

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.